Voloridge Investment Management LLC Sells 129,258 Shares of AtriCure, Inc. (NASDAQ:ATRC)

Voloridge Investment Management LLC lessened its holdings in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 33.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 260,412 shares of the medical device company's stock after selling 129,258 shares during the quarter. Voloridge Investment Management LLC owned approximately 0.53% of AtriCure worth $7,958,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also modified their holdings of the company. Johnson Financial Group Inc. increased its holdings in shares of AtriCure by 1,184.1% in the 4th quarter. Johnson Financial Group Inc. now owns 1,618 shares of the medical device company's stock worth $49,000 after buying an additional 1,492 shares during the last quarter. Heck Capital Advisors LLC purchased a new stake in AtriCure during the fourth quarter valued at approximately $60,000. Venturi Wealth Management LLC raised its holdings in shares of AtriCure by 1,337.6% during the fourth quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company's stock worth $69,000 after purchasing an additional 2,100 shares during the last quarter. KBC Group NV increased its holdings in AtriCure by 65.3% in the fourth quarter. KBC Group NV now owns 2,360 shares of the medical device company's stock valued at $72,000 after buying an additional 932 shares in the last quarter. Finally, State of Wyoming increased its holdings in AtriCure by 21.9% in the fourth quarter. State of Wyoming now owns 2,481 shares of the medical device company's stock valued at $76,000 after buying an additional 446 shares in the last quarter. Hedge funds and other institutional investors own 99.11% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on ATRC shares. Canaccord Genuity Group decreased their target price on shares of AtriCure from $66.00 to $52.00 and set a "buy" rating on the stock in a report on Friday, March 28th. Wall Street Zen raised shares of AtriCure from a "hold" rating to a "buy" rating in a research note on Saturday, May 24th. Needham & Company LLC reduced their price target on shares of AtriCure from $51.00 to $44.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. JMP Securities reaffirmed a "market outperform" rating and set a $60.00 target price on shares of AtriCure in a research note on Wednesday, April 30th. Finally, Oppenheimer increased their price target on shares of AtriCure from $36.00 to $45.00 and gave the stock an "outperform" rating in a research note on Thursday, February 13th. Ten equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $50.67.

Insider Buying and Selling at AtriCure

In related news, Director Karen Prange sold 6,100 shares of AtriCure stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total value of $232,532.00. Following the completion of the sale, the director now directly owns 17,828 shares in the company, valued at $679,603.36. This trade represents a 25.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 3.50% of the company's stock.

AtriCure Trading Up 1.5%

ATRC stock traded up $0.52 during mid-day trading on Friday, reaching $34.60. 62,713 shares of the stock traded hands, compared to its average volume of 647,426. The company has a market cap of $1.71 billion, a P/E ratio of -36.49 and a beta of 1.57. AtriCure, Inc. has a 52-week low of $18.94 and a 52-week high of $43.11. The company has a current ratio of 3.65, a quick ratio of 2.62 and a debt-to-equity ratio of 0.13. The stock's fifty day moving average is $32.32 and its 200-day moving average is $34.73.

AtriCure (NASDAQ:ATRC - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The medical device company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.11. AtriCure had a negative return on equity of 6.80% and a negative net margin of 9.61%. The company had revenue of $123.62 million for the quarter, compared to the consensus estimate of $122.92 million. During the same quarter last year, the company posted ($0.28) earnings per share. The company's revenue for the quarter was up 13.5% compared to the same quarter last year. As a group, sell-side analysts expect that AtriCure, Inc. will post -0.6 earnings per share for the current year.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.